Literature DB >> 2896355

Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency.

M E Conley1, A Lavoie, C Briggs, P Brown, C Guerra, J M Puck.   

Abstract

X chromosome-linked severe combined immunodeficiency (XSCID) is characterized by markedly reduced numbers of T cells, the absence of proliferative responses to mitogens, and hypogammaglobulinemia but normal or elevated numbers of B cells. To determine if the failure of the B cells to produce immunoglobulin might be due to expression of the XSCID gene defect in B-lineage cells as well as T cells, we analyzed patterns of X chromosome inactivation in B cells from nine obligate carriers of this disorder. A series of somatic cell hybrids that selectively retained the active X chromosome was produced from Epstein-Barr virus-stimulated B cells from each woman. To distinguish between the two X chromosomes, the hybrids from each woman were analyzed using an X-linked restriction fragment length polymorphism for which the woman in question was heterozygous. In all obligate carriers of XSCID, the B-cell hybrids demonstrated preferential use of a single X chromosome, the nonmutant X, as the active X. To determine if the small number of B-cell hybrids that contained the mutant X were derived from an immature subset of B cells, lymphocytes from three carriers were separated into surface IgM positive and surface IgM negative B cells prior to exposure to Epstein-Barr virus and production of B-cell hybrids. The results demonstrated normal random X chromosome inactivation in B-cell hybrids derived from the less mature surface IgM positive B cells. In contrast, the pattern of X chromosome inactivation in the surface IgM negative B cells, which had undergone further replication and differentiation, was significantly nonrandom in all three experiments [logarithm of odds (lod) score greater than 3.0]. These results suggest that the XSCID gene product has a direct effect on B cells as well as T cells and is required during B-cell maturation.

Entities:  

Mesh:

Year:  1988        PMID: 2896355      PMCID: PMC280149          DOI: 10.1073/pnas.85.9.3090

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Epstein-Barr virus binding sites on lymphocyte subpopulations and the origin of lymphoblasts in cultured lymphoic cell lines and in the blood of patients with infectious mononucleosis.

Authors:  M F Greaves; G Brown
Journal:  Clin Immunol Immunopathol       Date:  1975-03

Review 2.  The origin and development of human tumors studied with cell markers.

Authors:  P J Fialkow
Journal:  N Engl J Med       Date:  1974-07-04       Impact factor: 91.245

3.  Carrier detection in X-linked severe combined immunodeficiency based on patterns of X chromosome inactivation.

Authors:  J M Puck; R L Nussbaum; M E Conley
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

4.  Severe combined immunodeficiency with B lymphocytes: in vitro correction of defective immunoglobulin production by addition of normal T lymphocytes.

Authors:  R C Seeger; R A Robins; R H Stevens; R B Klein; D J Waldman; P M Zeltzer; S W Kessler
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

5.  Heterogeneity of lymphocyte subpopulations in severe combined immunodeficiency. Evidence against a stem cell defect.

Authors:  R H Buckley; R B Gilbertsen; R I Schiff; E Ferreira; S O Sanal; T A Waldmann
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

6.  Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation.

Authors:  A C Allison; T Hovi; R W Watts; A D Webster
Journal:  Lancet       Date:  1975-12-13       Impact factor: 79.321

7.  Hemizygous expression of glucose-6-phosphate dehydrogenase in erythrocytes of heterozygotes for the Lesch-Nyhan syndrome.

Authors:  W L Nyhan; B Bakay; J D Connor; J F Marks; D K Keele
Journal:  Proc Natl Acad Sci U S A       Date:  1970-01       Impact factor: 11.205

8.  Studies on the thymic dependence of the immunoglobulin classes of the mouse (38570).

Authors:  A D Bankhurst; P H Lambert; P A Miescher
Journal:  Proc Soc Exp Biol Med       Date:  1975-02

9.  X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells.

Authors:  I Scher; A Ahmed; D M Strong; A D Steinberg; W E Paul
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

10.  Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes.

Authors:  M Jondal; G Klein
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  34 in total

Review 1.  Primary T-lymphocyte immunodeficiencies.

Authors:  A Fischer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

Review 2.  Severe combined immunodeficiencies (SCID).

Authors:  A Fischer
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 3.  Genetics of human X-linked immunodeficiency diseases.

Authors:  R W Hendriks; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

4.  Unusual X chromosome inactivation in a mentally retarded girl with an interstitial deletion Xq27: implications for the fragile X syndrome.

Authors:  M Schmidt; A Certoma; D Du Sart; P Kalitsis; M Leversha; K Fowler; L Sheffield; I Jack; D M Danks
Journal:  Hum Genet       Date:  1990-03       Impact factor: 4.132

5.  Differential methylation at the 5' and the 3' CCGG sites flanking the X chromosomal hypervariable DXS255 locus.

Authors:  R W Hendriks; M E Kraakman; R G Mensink; R K Schuurman
Journal:  Hum Genet       Date:  1991-11       Impact factor: 4.132

Review 6.  Molecular and genetic basis of X-linked immunodeficiency disorders.

Authors:  J M Puck
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

7.  Wiskott-Aldrich syndrome carrier detection with the hypervariable marker M27 beta.

Authors:  G de Saint Basile; L D Notarangelo; C Bonaiti-Pellié; M Doussau; O Prolini; I W Craig; A Ugazio; C Griscelli; A Fischer
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

8.  Application of carrier testing to genetic counseling for X-linked agammaglobulinemia.

Authors:  R C Allen; R G Nachtman; H M Rosenblatt; J W Belmont
Journal:  Am J Hum Genet       Date:  1994-01       Impact factor: 11.025

9.  X chromosome inactivation analysis to distinguish sporadic cases of X-linked agammaglobulinaemia from common variable immunodeficiency.

Authors:  I Tsuge; H Matsuoka; T Abe; Y Kamachi; S Torii
Journal:  Eur J Pediatr       Date:  1993-11       Impact factor: 3.183

10.  B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans.

Authors:  Danielle T Avery; Elissa K Deenick; Cindy S Ma; Santi Suryani; Nicholas Simpson; Gary Y Chew; Tyani D Chan; Umamainthan Palendira; Jacinta Bustamante; Stéphanie Boisson-Dupuis; Sharon Choo; Karl E Bleasel; Jane Peake; Cecile King; Martyn A French; Dan Engelhard; Sami Al-Hajjar; Saleh Al-Muhsen; Klaus Magdorf; Joachim Roesler; Peter D Arkwright; Pravin Hissaria; D Sean Riminton; Melanie Wong; Robert Brink; David A Fulcher; Jean-Laurent Casanova; Matthew C Cook; Stuart G Tangye
Journal:  J Exp Med       Date:  2010-01-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.